Inhibition of CD40L with Frexalimab in Multiple Sclerosis
Sanofi
Patrick Vermersch; Cristina Granziera; Yang Mao-Draayer; Gary Cutter; Oleksandr Kalbus; Ivan Staikov; Michal Dufek; Stephane Saubadu; Raphael Bejuit; Philippe Truffinet; Biljana Djukic; Erik Wallstroem; Gavin Giovannoni; Frexalimab Phase 2 Trial Group